Advantage Investment Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Advantage Investment Management’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-89	Closed	-$2K	–	980
2019 Q2	$2K	Hold	89	–	–	﹤0.01%	887
2019 Q1	$2K	Hold	89	–	–	﹤0.01%	878
2018 Q4	$2K	Hold	89	–	–	﹤0.01%	931
2018 Q3	$2K	Hold	89	–	–	﹤0.01%	959
2018 Q2	$2K	Hold	89	–	–	﹤0.01%	892
2018 Q1	$2K	Hold	89	–	–	﹤0.01%	936
2017 Q4	$1K	Hold	89	–	–	﹤0.01%	985
2017 Q3	$2K	Hold	89	–	–	﹤0.01%	969
2017 Q2	$2K	Hold	89	–	–	﹤0.01%	995
2017 Q1	$2K	Sell	89 -1,910	-96%	-$45.7K	﹤0.01%	923
2016 Q4	$70K	Sell	1,999 -557	-22%	-$16.6K	0.03%	272
2016 Q3	$63K	Hold	2,556	–	–	0.02%	288
2016 Q2	$61K	Hold	2,556	–	–	0.03%	311
2016 Q1	$60K	Hold	2,556	–	–	0.03%	302
2015 Q4	$77K	Hold	2,556	–	–	0.04%	266
2015 Q3	$102K	Hold	2,556	–	–	0.06%	216
2015 Q2	$177K	Hold	2,556	–	–	0.09%	152
2015 Q1	$140K	Buy	+2,556	New	+$122K	0.08%	177

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Advantage Investment Management's AMAG Position: Q3 2019 in Review

Advantage Investment Management sold out of AMAG Pharmaceuticals (AMAG) in Q3 2019, closing a stake of 89 shares — an estimated $2K sold.

Advantage Investment Management first reported a position in AMAG in Q1 2015 and held it in 18 quarters. The position peaked at $177K in Q2 2015. 156 funds tracked by Wall St. Rank hold AMAG as of Q3 2019.

Advantage Investment Management reported no remaining AMAG Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Advantage Investment Management sold 89 AMAG Pharmaceuticals shares in Q3 2019, an estimated $2K.
Advantage Investment Management first reported a position in AMAG Pharmaceuticals in Q1 2015 and held it in 18 quarters.
Advantage Investment Management's AMAG Pharmaceuticals position peaked at $177K in Q2 2015.
156 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.